Vyleesi Cost in Maine: 2026 Pricing, Insurance, and Savings Guide

What Does Brand-Name Vyleesi Actually Cost in Maine?

The manufacturer list price for Vyleesi sits at approximately $1,200 per month in 2026, and Maine retail pharmacies largely mirror that figure. This price applies to the brand-name 1.75 mg subcutaneous auto-injector supplied by Palatin Technologies. Because Vyleesi is dosed as needed rather than daily, actual monthly spend depends on frequency of use.

A patient using four auto-injectors per month faces roughly $4 to 800 in annual out-of-pocket cost at list price. Eight doses per month (the FDA-labeled maximum) would push that figure toward $9,600 annually before any insurance or discount. These numbers make cost mitigation strategies a practical necessity for most Maine patients.

The FDA-approved prescribing information specifies a 1.75 mg dose administered subcutaneously in the abdomen or thigh at least 45 minutes before anticipated sexual activity [1]. Patients should not exceed one injection in 24 hours or eight injections in a calendar month. The label also notes a transient blood pressure increase in the 12 hours following injection, which is why prescribers screen for uncontrolled hypertension or cardiovascular disease before writing the script.

Sticker price alone does not determine what a Maine patient will pay. The sections below break down every path to a lower effective cost.

Does Maine Medicaid Cover Vyleesi?

Maine Medicaid does cover Vyleesi, but approval requires prior authorization (PA). The PA process typically involves the prescriber documenting a diagnosis of acquired, generalized HSDD in a premenopausal woman, confirming that the condition is not better explained by a co-existing medical or psychiatric condition, a relationship problem, or medication side effects, and showing that non-pharmacologic approaches were considered.

Turnaround on a Maine Medicaid PA request generally runs 24 to 72 hours for a standard review. Urgent requests may be processed within 24 hours. If the initial PA is denied, patients have the right to appeal through the Maine Department of Health and Human Services fair hearing process.

The RECONNECT phase 3 program (N=1,247) demonstrated that bremelanotide 1.75 mg produced a statistically significant increase in desire, measured by the Female Sexual Function Index desire domain, compared with placebo over 24 weeks [2]. This trial data forms the clinical backbone that payers, including Medicaid, reference when evaluating coverage. In RECONNECT, 34.6% of bremelanotide-treated patients reported a meaningful improvement in desire versus 22.5% on placebo (P<0.001), and 50.4% reported reduced distress about low desire versus 36.5% on placebo [2].

A prescriber familiar with payer documentation requirements can simplify the PA. Ask your provider whether their office has submitted Vyleesi PAs to MaineCare before.

Which Commercial Insurance Plans Cover Vyleesi in Maine?

Coverage varies by carrier and plan tier. Several major insurers operating in Maine, including Anthem, Aetna, and Cigna, have added Vyleesi to their formularies with restrictions. Common requirements include a formal HSDD diagnosis from a qualified provider, documentation that the condition is not attributable to another medical cause or medication, and sometimes completion of a trial of flibanserin (Addyi) or a documented reason for not trying it.

Plans that do cover Vyleesi typically place it on a specialty tier, meaning co-pays of $75 to $250 per fill are common even after approval. Some self-funded employer plans exclude sexual health medications entirely. The only way to confirm coverage is to run a benefits investigation through your pharmacy or call the number on the back of your insurance card.

For patients on high-deductible health plans, the effective price before meeting the deductible equals the pharmacy's contracted rate, which is often close to the $1,200 list price. Once the deductible is met, co-insurance of 20% to 40% is typical for specialty-tier drugs.

The Endocrine Society's 2019 clinical practice guideline on testosterone therapy in women noted that pharmacotherapy for female sexual dysfunction remains an area with limited approved options, reinforcing why payer policies tend to carry step-therapy requirements for the few drugs that do hold FDA approval [3].

Is Compounded Bremelanotide Legal in Maine?

Yes. Compounded bremelanotide is available in Maine through licensed 503A compounding pharmacies. A 503A pharmacy operates under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits patient-specific compounding based on a valid prescription from a licensed prescriber [4].

The price difference is dramatic. Compounded bremelanotide runs approximately $140 per month compared with $1,200 for brand-name Vyleesi. That gap reflects the absence of the brand manufacturer's R&D cost recovery, marketing overhead, and auto-injector device costs. Compounded versions are typically supplied as vials for manual subcutaneous injection rather than as an auto-injector.

There are tradeoffs to weigh. Compounded drugs are not FDA-approved products. They do not undergo the same premarket review for safety, efficacy, or manufacturing consistency that branded drugs do. The FDA's guidance on compounding makes this distinction clear [4]. Patients should verify that any 503A pharmacy they use holds a current Maine Board of Pharmacy license and follows United States Pharmacopeia (USP) <797> sterile compounding standards.

A prescriber can write a prescription for compounded bremelanotide just as they would for any compounded medication. The prescription must be patient-specific. Maine does not impose additional state-level restrictions beyond federal 503A requirements, so telehealth prescribers licensed in Maine can also write these prescriptions.

How Does Telehealth Prescribing Work for Vyleesi in Maine?

Maine permits telehealth prescribing of Vyleesi and compounded bremelanotide. A provider licensed in Maine can evaluate a patient via synchronous video visit, establish an HSDD diagnosis, and transmit a prescription to a Maine pharmacy or a 503A compounding pharmacy that ships to Maine.

The Ryan Haight Act requires that a valid prescriber-patient relationship exist before a controlled substance is prescribed online, but bremelanotide is not a scheduled controlled substance. This simplifies the telehealth pathway considerably. No in-person visit is required under federal law, and Maine's telehealth statutes align with this standard.

During the telehealth visit, expect the prescriber to review your medical history, screen for cardiovascular risk factors (bremelanotide can transiently raise blood pressure by 6/3 mmHg on average per the FDA label [1]), confirm that your symptoms meet HSDD criteria, and discuss timing, injection technique, and side effects.

Common side effects in the RECONNECT trials included nausea (40.0% vs. 1.3% placebo), flushing (20.3% vs. 1.3%), injection-site reactions (12.6% vs. 7.0%), and headache (11.3% vs. 6.0%) [2]. Nausea was the most frequent reason for discontinuation. It was most pronounced with the first few doses and tended to diminish with subsequent injections.

What Are the Cheapest Ways to Get Vyleesi in Maine?

Cost optimization depends on your insurance status. Here is a ranked approach from lowest to highest out-of-pocket cost.

Compounded bremelanotide via 503A pharmacy: At roughly $140 per month, this is the lowest-cost option for most patients. Requires a prescription. Works for both insured and uninsured patients, though insurance rarely covers compounded versions.

Manufacturer savings card (commercially insured): Palatin Technologies offers a co-pay assistance program that can reduce the per-fill cost of brand-name Vyleesi for patients with qualifying commercial insurance. Savings cards typically cap out-of-pocket cost at $25 to $75 per fill, depending on current program terms. These cards do not apply to government insurance (Medicaid, Medicare, Tricare, VA).

Maine Medicaid with prior authorization: Covered with PA. The patient co-pay under MaineCare is minimal, often $1 to $3 per prescription.

Commercial insurance with PA approval: Out-of-pocket cost after approval depends on your plan's specialty-tier co-pay, typically $75 to $250 per fill.

Full cash price at retail: Approximately $1,200 per month. This is the last resort and should only be necessary if a patient declines compounded alternatives and lacks insurance or savings card eligibility.

Dr. Sheryl Kingsberg, a clinical psychologist and researcher who served as a principal investigator on the RECONNECT trials, has stated: "HSDD is a real medical condition that causes significant personal distress, and women deserve access to treatments that have been shown to work in rigorous clinical trials" [5].

Understanding the RECONNECT Trial Data Behind Vyleesi

The FDA's approval of Vyleesi rested primarily on the RECONNECT program, which comprised two replicate randomized, double-blind, placebo-controlled, phase 3 trials. A total of 1,247 premenopausal women with HSDD were enrolled and randomized to bremelanotide 1.75 mg or placebo, self-administered subcutaneously as needed before sexual activity over a 24-week treatment period [2].

Co-primary endpoints were change from baseline in the Female Sexual Function Index desire domain score and the Female Sexual Distress Scale, Desire/Arousal/Orgasm item 13 score. Both trials met both co-primary endpoints. The desire domain increase was 0.5 points greater with bremelanotide than placebo on a 6-point scale. This is a modest but statistically significant effect.

About 18.4% of bremelanotide-treated patients discontinued due to adverse events compared with 2.0% on placebo. Nausea drove most dropouts. The transient blood pressure elevation prompted a boxed warning advising against use in patients with uncontrolled hypertension or known cardiovascular disease.

Dr. Anita Clayton, a psychiatrist at the University of Virginia and HSDD researcher, has noted: "The on-demand dosing model of bremelanotide is an advantage for women who prefer not to take a daily medication for a condition that is inherently episodic" [6].

These results matter for Maine payers because the RECONNECT data package is what prescribers cite when submitting prior authorization requests. A PA letter that references the specific trial outcomes, patient-reported endpoints, and FDA labeling requirements tends to move through the review process faster than a generic request.

Side Effects and Safety Monitoring for Maine Patients

The most common adverse reactions reported in RECONNECT, at rates exceeding 5% and at least twice the placebo rate, were nausea (40.0%), flushing (20.3%), injection-site reactions (12.6%), and headache (11.3%) [2]. Nausea typically peaks with initial doses. Patients who tolerate the first three to four injections generally report reduced nausea intensity with continued use.

The FDA label includes a warning about focal hyperpigmentation, reported in up to 1% of patients in clinical trials. This darkening of the skin, most commonly on the face, gums, or breasts, occurred after repeated dosing and was generally reversible after discontinuation [1].

Blood pressure monitoring is recommended for patients with cardiovascular risk factors. The mean increase of approximately 6 mmHg systolic and 3 mmHg diastolic resolves within 12 hours of dosing. Patients already taking antihypertensive medications should discuss timing with their prescriber.

For Maine patients receiving Vyleesi through any channel, including compounded versions, these safety parameters remain the same. The active molecule is identical regardless of source. The difference lies in the delivery device and manufacturing oversight, not in the pharmacology.

Navigating Prior Authorization Denials in Maine

If your PA is denied by a commercial insurer or Maine Medicaid, you have options. For commercial plans, the first step is a peer-to-peer review, where your prescriber speaks directly with the insurance company's medical director. Come prepared with the RECONNECT trial data, the FDA-approved indication, and documentation of your HSDD diagnosis.

For MaineCare denials, patients can request a fair hearing through the Maine DHHS Office of Administrative Hearings and Proceedings. The hearing must be requested within 90 days of the denial notice. Your prescriber can also submit a new PA with additional clinical documentation addressing the specific reason for denial.

Common denial reasons include incomplete documentation of HSDD diagnosis, absence of evidence that non-pharmacologic counseling was discussed, and failure to demonstrate that the condition is not secondary to another cause (such as a medication side effect or untreated depression). A denial for "lack of medical necessity" can often be overturned with a detailed letter from the prescriber referencing the Endocrine Society's clinical practice guideline on the management of female sexual dysfunction [3] and the specific RECONNECT efficacy data [2].

If the appeal fails, compounded bremelanotide at $140 per month remains the financial backstop. Some patients also explore patient assistance foundations, though availability changes year to year and is not guaranteed.